Stockscreener 앱 받기
57.06
3.91%
-2.32
시간 외 거래:
57.06
전일 마감가:
$59.38
열려 있는:
$59.77
하루 거래량:
2.53M
Relative Volume:
2.68
시가총액:
$1.95B
수익:
$55.63M
순이익/손실:
$-158.10M
주가수익비율:
-6.7766
EPS:
-8.4202
순현금흐름:
$-203.94M
1주 성능:
-14.96%
1개월 성능:
-23.88%
6개월 성능:
-20.84%
1년 성능:
+2.59%
1일 변동 폭
$57.04
$60.98
1주일 범위
$56.21
$69.84
52주 변동 폭
$33.40
$109.00
넥타테라퓨틱스 Stock (NKTR) Company Profile
명칭
Nektar Therapeutics
전화
(415) 482-5300
주소
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Compare NKTR vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
57.06 | 1.95B | 55.63M | -158.10M | -203.94M | -8.4202 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
넥타테라퓨틱스 Stock (NKTR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-24 | 개시 | Wedbush | Neutral |
| 2026-03-17 | 개시 | TD Cowen | Buy |
| 2026-02-10 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2025-11-26 | 개시 | Citigroup | Buy |
| 2025-06-24 | 재확인 | BTIG Research | Buy |
| 2025-06-24 | 재확인 | H.C. Wainwright | Buy |
| 2025-04-11 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-03-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-01-08 | 개시 | B. Riley Securities | Buy |
| 2024-12-10 | 개시 | H.C. Wainwright | Buy |
| 2024-11-04 | 개시 | Piper Sandler | Overweight |
| 2024-09-30 | 재개 | BTIG Research | Buy |
| 2024-06-28 | 개시 | Rodman & Renshaw | Buy |
| 2023-11-20 | 재개 | JP Morgan | Underweight |
| 2023-11-09 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-05-10 | 업그레이드 | Jefferies | Underperform → Hold |
| 2023-02-24 | 다운그레이드 | Jefferies | Hold → Underperform |
| 2022-08-08 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-05-31 | 재개 | Jefferies | Hold |
| 2022-04-18 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-03-15 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2022-03-15 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-03-14 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2022-03-14 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-03-14 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-03-14 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2022-03-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-11-08 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-09-10 | 개시 | BofA Securities | Neutral |
| 2021-06-28 | 업그레이드 | Stifel | Hold → Buy |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-02-22 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2021-01-06 | 개시 | Stifel | Hold |
| 2020-09-14 | 개시 | JP Morgan | Neutral |
| 2020-06-10 | 다운그레이드 | CFRA | Hold → Sell |
| 2020-05-12 | 재확인 | H.C. Wainwright | Neutral |
| 2020-04-22 | 개시 | The Benchmark Company | Buy |
| 2020-03-30 | 업그레이드 | Goldman | Sell → Neutral |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-02-03 | 업그레이드 | Mizuho | Neutral → Buy |
| 2019-10-24 | 개시 | Oppenheimer | Perform |
| 2019-10-08 | 다운그레이드 | Goldman | Buy → Sell |
| 2019-08-09 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-08-09 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-08-09 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2019-03-15 | 개시 | SVB Leerink | Mkt Perform |
| 2018-12-13 | 개시 | Goldman | Buy |
| 2018-06-11 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2018-06-04 | 재확인 | H.C. Wainwright | Buy |
| 2018-04-20 | 개시 | Seaport Global Securities | Buy |
| 2018-04-13 | 재개 | Piper Jaffray | Overweight |
| 2018-04-06 | 재확인 | Mizuho | Buy |
| 2018-04-02 | 재개 | H.C. Wainwright | Buy |
모두보기
넥타테라퓨틱스 주식(NKTR)의 최신 뉴스
Nektar Therapeutics Director Roy Whitfield Reports Acquisition of RSUs and Stock Options - Kalkine Media
Form 4 Nektar Therapeutics For: 25 September By Investing.com - Investing.com Nigeria
Nektar Therapeutics (NKTR) grants a director 2,000 shares upon vesting and options to buy 4,000 more. - Stock Titan
A director receives 2,000 stock units alongside 4,000 options at Nektar Therapeutics (NKTR). - Stock Titan
Director Robert Chess also received 2,000 stock units from Nektar Therapeutics (NKTR), vesting in one year. - Stock Titan
Director Diana Brainard receives 2,000 stock units from Nektar Therapeutics (NKTR), vesting in one year. - Stock Titan
Nektar Therapeutics awarded $90 million in jury verdict against Eli Lilly By Investing.com - Investing.com South Africa
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - prnewswire.com
Eli Lilly owes Nektar $90 mln in drug collaboration dispute, US jury says - Reuters
Microsoft, Nike, Nektar Therapeutics - TradingView
Nektar Therapeutics Wins $90M Lilly Verdict - grafa.com
Nektar Therapeutics stock rises on $90M jury verdict vs Lilly - Investing.com
Lilly ordered to pay Nektar $90M in damages over rezpeg dispute - FirstWord
Jury awards Nektar Therapeutics $90M in rezpeg dispute with Eli Lilly - Dealroom
Nektar prevails in legal battle with Lilly over broken rezpeg partnership - BioSpace
Update: Nektar Wins $90 Million Jury Verdict Against Eli Lilly Over Rezpegaldesleukin Deal - Yahoo Finance
Eli Lilly Did Breach Implied Covenant of Good Faith With Nektar Therapeutics, Jury FundsEli Lilly (NYS - Benzinga
BTIG reiterates Buy rating on Nektar Therapeutics, $178 price target - TradingView
Nektar Gets $90 Million Jury Award in Breach Suit Against Eli Lilly — Update - Morningstar
Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data - Yahoo Finance
Why is Nektar Therapeutics stock climbing today? - Investing.com
Form 8K Nektar Therapeutics For: 25 September By Investing.com - Investing.com India
Nektar Therapeutics awarded $90 million in jury verdict against Eli Lilly - Investing.com Canada
Nektar gains 5% as jury awards $90M plus interest in Lilly trial - TradingView
Nektar Therapeutics awarded $90M jury verdict against Eli Lilly over rezpegaldesleukin dispute - TradingView
Nektar TherapeuticsJury Finds Lilly Breached Implied Covenant Of Good Faith In License Agreement - TradingView
Eli Lilly Hit With $90M Verdict In Nektar's Rezpeg Breach Suit - law360.com
Nektar Therapeutics (NKTR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Nektar Therapeutics stock gains 2.98 percent on trial watch - AD HOC NEWS
Wedbush maintains Neutral rating on Nektar Therapeutics, $50 price target - TradingView
NKTR Stock Soars After Nektar Reports Positive Atopic Dermatitis Trial Results - Stocktwits
Nektar Therapeutics stock falls 9.6 percent as patent case weighs - AD HOC NEWS
Nektar Therapeutics (NKTR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - accessnewswire.com
Nektar Therapeutics drops as jury deliberates in Eli Lilly dispute over Rezpeg - TradingView
How Investors Are Reacting To Nektar Therapeutics (NKTR) Index Reclassification - simplywall.st
Nektar Therapeutics(NasdaqCM: NKTR) added to S&P Biotechnology Select Industry Index - marketscreener.com
Nektar Therapeutics(NasdaqCM:NKTR) dropped from S&P Pharmaceuticals Select Industry Index - marketscreener.com
Nektar Therapeutics (NKTR), What Is Drawing Fresh Attention Now? - simplywall.st
Lilly Left Nektar Drug 'Damaged Goods,' Jury Told At Trial End - law360.com
Nektar Therapeutics stock gains after Q2 loss narrows - AD HOC NEWS
Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Investors to Connect - ACCESS Newswire
Nektar Therapeutics options flow shows bullish bets against a bearish tape - Investing.com
Nektar Therapeutics (NKTR) Reports Q2 Loss, Misses Revenue Estimates - Eastern Progress
Lilly Owes Nektar $1B If It Breached Rezpeg Deal, Jury Told - Law360
Nektar CEO Opens Door To Finance Questions In Eli Lilly Trial - Law360
Nektar to Release 24-Week Off-Treatment Data for Rezpegaldesleukin in Alopecia Areata - The Clinical Trial Vanguard
Eli Lilly 'Sabotaged' Rezpeg's Development, Nektar Tells Jury - Law360
Lancet Phase 2b REZOLVE-AD Data Could Be A Game Changer For Nektar Therapeutics (NKTR) - simplywall.st
Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Stockholders to Connect - ACCESS Newswire
Nektar Therapeutics (NKTR) Lands Lancet Backing, Is The Upside Already Priced In? - simplywall.st
2026-09-06 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Stockholders to Connect | NDAQ:NKTR | Press Release - stockhouse.com
넥타테라퓨틱스 (NKTR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):